Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
HAYWARD, Calif.–(BUSINESS WIRE)–
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas, NV.
Pulse Biosciences’ Management is scheduled to present on Wednesday, May 13, at 4:35 pm PT. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations” page of the company’s investor website at http://investors.pulsebiosciences.com/.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue as well as initiating regulated cell death. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.
Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260508321314/en/
Investor Contact:
Pulse Biosciences, Inc.
Jon Skinner, CFO
[email protected]
Or
Gilmartin Group
Philip Trip Taylor
415.937.5406
[email protected]
KEYWORDS: California United States North America
INDUSTRY KEYWORDS: Biotechnology Health Cardiology Medical Devices
MEDIA:
| Logo |
 |